COVID-19 pandemic: The deadly respiratory disease of 21st century
The sudden outbreak of 2019 novel coronavirus (2019-nCoV) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated from Wuhan, China. SARS-CoV-2 causes severe respiratory illness and becomes a major threat for humanity. Recently the entire scientist, researchers and physicians all over the countries focused to find the treatment of this pandemic disease. Numerous drugs and or vaccines have been trialed for prevention and treatment against 2019-nCoV but no therapy has been shown effective to date. Currently, numerous vaccines are under clinical investigation and mRNA-1273 vaccine (LNP- encapsulated mRNA vaccine encoding S protein) from Moderna is ahead. Although chloroquine, hydroxychloroquine, remdesivir and many other drugs had recommended against SARS-CoV-2, but still they are not the guarantee treatment of COVID-19. Recently, India, America, Russia and China introduced vaccines against COVID-19 in the market, however assurance of their 100% effectiveness are doubtful. The speed of daily new cases threatens the world and urges the scientist to crack this pandemic condition.
2. Jain AK, Sharma S, et al. 1,3,4-Thiadiazole and Its Derivatives: A Review on Recent Progress in Biological Activities. Chem Biol Drug Des. 2013; 81(85): 557-576.
3. Vaidya A, Jain S, et al. Metabotropic Glutamate Receptors: A Review on Prospectives and Therapeutic Aspects. Mini-Rev Med Chem. 2013; 12: 1967-1981.
4. Jain AK, Vaidya A, et al. Recent Developments and Biological Activities of Thiazolidinone Derivatives: A Review. Bioorg Med Chem. 2012; 20: 3378-3395.
5. Wong JEL, Leo YS, et al. COVID-19 in Singapore—current experience: criti- cal global issues that require attention and action. JAMA. 2020; 323(13): 1243-1244.
6. Ramaiah A, Arumugaswami V. Insights into cross-species evolution of novel human coronavirus 2019-nCoV and defining immune determinants for vaccine development. bioRxiv. 2020; accessed on 30 June 2020.
7. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect. 2020; S1684-1182(20): 30082-30087.
8. Walls AC, Xiong X, et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion. Cell. 2019; 176: 1026–1039.
9. Hoffmann M, Kleine-Weber H, et al. SSARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; 181(2): 271-280.
10. Lu R, Zhao X, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395: 565–574.
11. Zhou P, Yang XL, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579: 270–273.
12. Lam TT, Shum MH, et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature. 2020; 583(7815): 282-285.
13. Zhang H, Kang Z, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020; accessed on 05 July 2020.
14. Guan W, Ni Z, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382: 1708-1720.
15. Lauer SA, Grantz KH, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020; accessed on 15 December 2020.
16. Wang W, Xu Y, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020; 323(18): 1843–1844.
17. To KK, Tsang OT, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020; 20: 565-574.
18. Xiang F, Wang X, et al. Antibody detection and dynamic characteristics in patients with COVID-19. Clin Infect Dis. 2020; 71(8): 1930-1934.
19. Guo L, Ren L, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020; 71(15): 778-785.
20. Vaidya A, Jain S, et al. Pectin-metronidazole prodrug bearing microspheres for colon targeting. J Saudi Chem Soc. 2012; 19(3): 257–264.
21. Vaidya A, Jain S, et al. Synthesis and Biological Activities of Oxadiazole Derivatives: A Review. Mini-Rev Med Chem. 2016; 16(10): 825-845.
22. Jain S, Pattnaik S, et al. 2017 Anticancer Potential of Thiazole Derivatives: A Retrospective Review. Mini-Rev Med Chem. 2016; 18(8): 640-655.
23. Jain S, Pathak K, et al. Molecular therapy using siRNA: Recent trends and advances of multi target inhibition of cancer growth International. J Biolo Macromol. 2018; 116: 880-892.
24. Jain S, Jain S, et al. Gastrointestinal Protective Effect of Zizyphus xylopyrus (Retz) Wild Leaf Extract Against Indomethacin and HCl-EtOH Induced Ulcers. Curr Trad Med. 2019; 5(2): 140-146.
25. Vaidya A, Pathak D, et al. 1,3,4‐oxadiazole and its Derivatives: A Review on Recent Progress in Anticancer Activities. Chem Biol Drug Des. 2020; accessed on 24 October 2020.
26. Vaidya A, et al. Anticancer agents based on vulnerable components in a signalling pathway. Mini-Rev Med Chem. 2020; 20(10): 886-907.
27. Jain S, Chandra V, et al. Comprehensive review on current developments of quinoline-based anticancer agents. Arabian J Chem. 2019; 12(8): 4920-4946.
28. Jain S, Jain A, et al. Preliminary phytochemical, pharmacognostical and physico-chemical evaluation of Cedrus deodara heartwood. J Pharmacog Phytochem. 2014; 3(1): 91-95.
29. Jain S, Vaidya A, et al. Pharmacognostic and phytochemical investigations of the leaves of zizyphusXylopyrus (retz) willd. Int J Pharm Pharmaceut Sci. 2011; 3: 122-125.
30. Vaidya A, Jain AK, et al. Predicting anti-cancer activity of quinoline derivatives: CoMFA and CoMSIA approach. J Enzy Inhibit Med Chem. 2011; 26(6): 854-861.
31. Jain AK, Veerasamy R, et al. QSAR analysis of some novel sulfonamides incorporating 1,3,5-triazine derivatives as carbonic anhydrase inhibitors. Med Chem Res. 2010; 19: 1191-1202.
32. Agrawal RK, Jain AK, et al. QSAR analysis of B-ring-modified diaryl ether derivatives as a InhA inhibitors. Med Chem Res. 2012; 21: 145-151.
33. Bhatiya R, Vaidya A, et al. QSAR analysis of furanone derivatives as potential COX-2 inhibitors: kNN MFAapproach. J Saudi Chem Soc. 2014; 18(6): 977–984.
34. Vaidya A, Jain S, et al. Quantitative Structure-Activity Relationships: A Novel Approach of Drug Design and Discovery. J Pharm Sci Pharmacol. 2014; 1(3): 219-232.
35. Vaidya A, Jain S, et al. Computational Analysis of Quinoline Derivatives as Potent Topoisomerase-II Inhibitors. Med Chem Res. 2015; 24(1): 383-393.
36. Vaidya A, Jain AK, et al. CoMFA, CoMSIA, kNN MFA and Docking studies of 1,2,4-Oxadiazole derivatives as potent Caspase-3 activators. Arabian J Chem. 2017; 10(2): S3936-S3946
37. Jain S, Vaidya A, et al. Computational analysis of benzyl vinylogous derivatives as potent PDE3B inhibitors. Arabian J Chem. 2017; 10: S109-S113
38. Vaidya A, Jain S, et al. Synthesis of 1,2,4-oxadiazole derivatives: anticancer and 3D QSAR studies. Monatshefte für Chem- Chem Monthly. 2020; 151: 385-395.
39. Vaidya A, Jain S, et al. Simvastatin-Loaded PEGylated Solid Lipid Nanoparticles: Lipid Functionalization to Improve Blood Circulation. Bionanoscience. 2020; 10: 773–782.
40. Khan T, Vaidya A, et al. Meropenem Loaded Pectin Microspheres for Colon Delivery. Asian J Biomat Res. 2018; 4(4): 8-20.
41. Vaidya A, Jain R, et al. Design and Development of Mucoadhesive Thiolated Chitosan Microspheres for Colonic Drug Delivery. J Bionanosci. 2018;12(4): 590-598.
42. Pathak K, Vaidya A, et al. Confronting Penetration Threshold via Fluidic Terpenoid Nanovesicles. Curr Drug Del. 2018; 15(6): 765-776.
43. Vaidya A, Jain S, et al. Dendrimers: Nanosized Multifunctional Platform for Drug Delivery. Drug Deli Lett. 2018; 8(1): 3 – 19.
44. Jain P, Vaidya A, et al. Ethyl Cellulose Coated Chitosan Microspheres of Metronidazole as Potential Anti-Amoebic Agent. J Bionanosci. 2018; 11(6): 599-607.
45. Vaidya A, Jain S, et al. Metronidazole loaded eudragit coated alginate beads for colon targeting. Int J Pharma Healthcare Res. 2014; 2: 81 – 86.
46. Jain S, Jain AP, et al. Nanotechnology: An emerging area in the field of dentistry. J Dental Sci. 2013; XX: 9-13.
47. Vaidya A, Agarwal A, et al. Bioconjugation as a novel platform for targeted drug delivery: A Review. Curr Pharm Des. 2011; 17(11): 1108-1125.
48. Vaidya A, Jain A, et al. Metronidazole Loaded Pectin Microspheres for Colon Targeting. J Pharm Sci. 2009; 98: 4229-4236.
49. Colson, P, Rolain, JM, et al. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020; 55(3): 105923.
50. Gao J, Tian Z, et al. Breakthrough: chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020; 14: 72–73.
51. Zhonghua JHHHXZZ. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Chinese. 2020; 43: 185–188.
52. Gautret P, Lagier JC, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020; 56(1): 105949.
53. Derendorf H, Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. Int J Antimicrob Agents. 2020; 55(6): 106007.
54. Matrosovich M, Herrler G, et al. Sialic acid receptors of viruses. Top Curr Chem. 2015; 367: 1–28.
55. Fantini J, Scala CD, et al. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020; 55(5): 105960.
56. Randolph VB, Winkler G, et al. Acidotropic amines inhibit proteolytic processing of flaviviruspr M protein. Virology. 1990; 174: 450–458.
57. Fang L, Karakiulakis G, et al. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med; 2020; 8(4): e21.
58. Zhou F, Yu T, et al. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-1062.
59. Dayer MR, Gassabi ST, et al. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study. Arch Clin Infect Dis. 2017; 12(4): 1-7.
60. Chu CM, Cheng VC, et al. HKU/UCH SARS Study GroupRole of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004; 59: 252-256.
61. Ye XT, Luo YL, et al. Clinical Efficacy of Lopinavir/Ritonavir in the Treatment of Coronavirus Disease 2019. Eur Rev Med Pharmacol Sci. 2020; 24: 3390-3396.
62. Cao B, Wang Y, et al. Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382: 1787-1799.
63. ChiCTR2000029387 Comparison of efficacy and safety of three antiviral regimens in patients with mild to moderate 2019-nCoV pneumonia: a randomized controlled trial
64. NCT04276688 Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
65. de-Wit E, Feldmann F, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci USA. 2020; 117: 6771–6776.
66. Grein J, Ohmagari N, et al. A Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020; 382: 24.
67. Wang Y, Zhang D, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395: 1569-1578.
68. Wang M, Cao R, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCov) in vitro. Cell Res. 2020; 30: 269–271.
69. Sissoko D, Laouenan C, et al. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016; 13(3): e1001967.
70. Cai Q, Yang M, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engr. 2020; 6(10): 1192-1198.
71. Chen C, Zhang Y, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. medRxiv. 2020; accessed on 23 November 2020.
72. Khamitov RA, Loginova S, et al. Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures. Vopr Virusol. 2008; 53(4): 9-13.
73. Xu K, Chen Y, et al. Clinical efficacy of Arbidol in patients with 2019 novel corona virus infected pneumonia: a retrospective cohort study. Lancet. 2020; accessed on 16 November 2020.
74. Gotz V, Magar L, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep. 2016; 6: 23138.
75. Schmith VD, Zhou J, et al. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19. medRxiv. 2020; 108(4): 762-765.
76. Momekov G, Momekova D. et al. Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view. medRxiv. 2020; (Epub ahead of print).
77. Patri A. et al. Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment? J Am Acad Dermatol. 2020; accessed on 04 November 2020.
78. Zhang H, Baker A. Recombinant human ace2: acing out angiotensin II in ards therapy. Crit Care. 2017; 21(1): 305.
79. Sheahan TP, Sims AC, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple 1endemic, epidemic and batcoronavirus. bioRxiv. 2020; accessed on 16 December 2020.
80. Zorzitto J, Galligan CL, et al. Characterization of the antiviral effects of interferon- α against a SARS-like corona virus infection in vitro. Cell Res. 2006; 16: 220–229.
81. Haagmans BL, Kuiken T, et al. ADME Pegylated interferon- α protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med. 2004; 10: 290–293.
82. Lokugamage KG, Schindewolf C, et al. SARS-CoV-2 sensitive to type I interferon pretreatment. bioRxiv. 2020; accessed on 10 December 2020.
83. Dong L, Hu S, et al. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020; 14: 58–60.
84. NCT04315948 Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy)
85. Hung IFN, Lung KC, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238), 1695‐1704.
86. Casadevall A, Dadachova E, et al. Passive antibody therapy for infectious diseases. Nat Rev Microbiol. 2004; 2(9): 695-703.
87. Shen C, Wang Z, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16): 1582-1589.
88. Duan K, Liu B, The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study. medRxiv. 2020; accessed on 14 December 2020.
89. Cao W, Liu X, et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis. 2020; 7(3): 1-6.
90. Bloch EM, Shoham S, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6): 2757-2765.
91. Huang C, Wang Y, et al. Clinical features of patients infected with 2019 novel corona virus in Wuhan China. Lancet. 2020; 395(10223): 497-506.
92. Chen N, Zhou M, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel corona virus pneumonia in Wuhan, China:a descriptive study. Lancet. 2020; 395(10223): 507-513.
93. De Diego ML, Nieto-Torres JL, et al. Inhibition of NF-kappa B-mediated in-flammation in severe acute respiratory syndrome corona virus-infected mice in-creases survival. J Virol. 2014; 88: 913–924.
94. Schoeman D, Fielding BC. Corona virus envelope protein: current knowledge. Virol J. 2019; 16: 69.
95. Michot JM, Albiges L, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020; 31(7):961-964.
96. Xu X, Han M, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. PNAS. 2020; 117(20): 10970-10975.
97. Sanchez GA, Reinhardt A, et al. JAK1/2 inhibition with baricitinib in the treatment of auto inflammatory interferonopathies . J Clin Invest. 2018; 128(7): 3041–3052.
98. Tobinick E. TNF-αinhibition for potentialtherapeutic modulation of SARScoronavirus infection. Curr Med Res Opin. 2004; 20(1): 239-240.
99. ChiCTR2000030089 Chinese Trial Clinical Registry A randomized, open-label, controlled trial for the efficacy and safety of Adalimumab Injection in the treatment of patients with severe novel coronavirus pneumonia (COVID 19)
100. Li W, Ren G, et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ. 2012; 19: 1505-15013.
101. Leng Z, Zhu R, et al. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020; 11(2): 216-228.
102. Liang B, Chen J, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord china. Medicine. 2020; 99(31): e21429.
103. Traggiai E, Becker S, et al. An efficient method to make human monoclonal antibodies from mem- ory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004; 10: 871–875.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.